401 related articles for article (PubMed ID: 26968228)
1. Early results of multicenter phase II trial of perioperative oxaliplatin and capecitabine without radiotherapy for high-risk rectal cancer: CORONA I study.
Kamiya T; Uehara K; Nakayama G; Ishigure K; Kobayashi S; Hiramatsu K; Nakayama H; Yamashita K; Sakamoto E; Tojima Y; Kawai S; Kodera Y; Nagino M;
Eur J Surg Oncol; 2016 Jun; 42(6):829-35. PubMed ID: 26968228
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of neoadjuvant chemoradiotherapy with oxaliplatin and capecitabine for rectal cancer.
Zhao L; Bai C; Shao Y; Guan M; Jia N; Xiao Y; Qiu H; Zhang F; Yang T; Zhong G; Chen S
Cancer Lett; 2011 Nov; 310(2):134-9. PubMed ID: 21782322
[TBL] [Abstract][Full Text] [Related]
3. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer.
Rödel C; Liersch T; Hermann RM; Arnold D; Reese T; Hipp M; Fürst A; Schwella N; Bieker M; Hellmich G; Ewald H; Haier J; Lordick F; Flentje M; Sülberg H; Hohenberger W; Sauer R
J Clin Oncol; 2007 Jan; 25(1):110-7. PubMed ID: 17194912
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant sandwich treatment with oxaliplatin and capecitabine administered prior to, concurrently with, and following radiation therapy in locally advanced rectal cancer: a prospective phase 2 trial.
Gao YH; Lin JZ; An X; Luo JL; Cai MY; Cai PQ; Kong LH; Liu GC; Tang JH; Chen G; Pan ZZ; Ding PR
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1153-60. PubMed ID: 25442042
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant capecitabine and oxaliplatin (XELOX) combined with bevacizumab for high-risk localized rectal cancer.
Hasegawa J; Nishimura J; Mizushima T; Miyake Y; Kim HM; Takemoto H; Tamagawa H; Noura S; Fujii M; Fujie Y; Kato T; Miwa H; Takemasa I; Ikeda M; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
Cancer Chemother Pharmacol; 2014 May; 73(5):1079-87. PubMed ID: 24595805
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of capecitabine and oxaliplatin administered prior to and then concomitant to radiotherapy in high risk locally advanced rectal cancer.
Gao YH; An X; Sun WJ; Cai J; Cai MY; Kong LH; Lin JZ; Liu GC; Tang JH; Wu XJ; Chen G; Pan ZZ; Ding PR
J Surg Oncol; 2014 Apr; 109(5):478-82. PubMed ID: 24288203
[TBL] [Abstract][Full Text] [Related]
7. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study.
Fernández-Martos C; Pericay C; Aparicio J; Salud A; Safont M; Massuti B; Vera R; Escudero P; Maurel J; Marcuello E; Mengual JL; Saigi E; Estevan R; Mira M; Polo S; Hernandez A; Gallen M; Arias F; Serra J; Alonso V
J Clin Oncol; 2010 Feb; 28(5):859-65. PubMed ID: 20065174
[TBL] [Abstract][Full Text] [Related]
8. A Feasibility Study of Neoadjuvant XELOX Without Radiotherapy for Locally Advanced Lower Rectal Cancer.
Ueki T; Manabe T; Inoue S; Ienaga J; Yamanaka N; Egami T; Ishikawa M; Konomi H; Ikubo A; Nagayoshi K; Nakamura M; Tanaka M
Anticancer Res; 2016 Feb; 36(2):741-7. PubMed ID: 26851033
[TBL] [Abstract][Full Text] [Related]
9. [Feasibility study on Xelox (capecitabine plus oxapliplatin) in the volumetric modulated arc therapy (VMAT)-based preoperative chemoradiotherapy for locally advanced rectal cancer].
Xiao L; Huang R; You K; Chang H; Qiu B; Xiao W; Chen L; Gao Y; Liu M
Zhonghua Wei Chang Wai Ke Za Zhi; 2014 Mar; 17(3):219-24. PubMed ID: 24671807
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant oxaliplatin and capecitabine and bevacizumab without radiotherapy for poor-risk rectal cancer: N-SOG 03 Phase II trial.
Uehara K; Hiramatsu K; Maeda A; Sakamoto E; Inoue M; Kobayashi S; Tojima Y; Yoshioka Y; Nakayama G; Yatsuya H; Ohmiya N; Goto H; Nagino M
Jpn J Clin Oncol; 2013 Oct; 43(10):964-71. PubMed ID: 23935207
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.
Chua YJ; Barbachano Y; Cunningham D; Oates JR; Brown G; Wotherspoon A; Tait D; Massey A; Tebbutt NC; Chau I
Lancet Oncol; 2010 Mar; 11(3):241-8. PubMed ID: 20106720
[TBL] [Abstract][Full Text] [Related]
12. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial.
Rödel C; Graeven U; Fietkau R; Hohenberger W; Hothorn T; Arnold D; Hofheinz RD; Ghadimi M; Wolff HA; Lang-Welzenbach M; Raab HR; Wittekind C; Ströbel P; Staib L; Wilhelm M; Grabenbauer GG; Hoffmanns H; Lindemann F; Schlenska-Lange A; Folprecht G; Sauer R; Liersch T;
Lancet Oncol; 2015 Aug; 16(8):979-89. PubMed ID: 26189067
[TBL] [Abstract][Full Text] [Related]
13. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C).
Dewdney A; Cunningham D; Tabernero J; Capdevila J; Glimelius B; Cervantes A; Tait D; Brown G; Wotherspoon A; Gonzalez de Castro D; Chua YJ; Wong R; Barbachano Y; Oates J; Chau I
J Clin Oncol; 2012 May; 30(14):1620-7. PubMed ID: 22473163
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
Chau I; Brown G; Cunningham D; Tait D; Wotherspoon A; Norman AR; Tebbutt N; Hill M; Ross PJ; Massey A; Oates J
J Clin Oncol; 2006 Feb; 24(4):668-74. PubMed ID: 16446339
[TBL] [Abstract][Full Text] [Related]
15. Postoperative XELOX therapy for patients with curatively resected high-risk stage II and stage III rectal cancer without preoperative chemoradiation: a prospective, multicenter, open-label, single-arm phase II study.
Mizushima T; Ikeda M; Kato T; Ikeda A; Nishimura J; Hata T; Matsuda C; Satoh T; Mori M; Doki Y
BMC Cancer; 2019 Sep; 19(1):929. PubMed ID: 31533662
[TBL] [Abstract][Full Text] [Related]
16. Phase II Trial of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin, and Bevacizumab Followed by Surgery and Postoperative 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX), and Bevacizumab in Patients With Locally Advanced Rectal Cancer: 5-Year Clinical Outcomes ECOG-ACRIN Cancer Research Group E3204.
Landry JC; Feng Y; Prabhu RS; Cohen SJ; Staley CA; Whittington R; Sigurdson ER; Nimeiri H; Verma U; Benson AB
Oncologist; 2015 Jun; 20(6):615-6. PubMed ID: 25926352
[TBL] [Abstract][Full Text] [Related]
17. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control.
Glynne-Jones R; Counsell N; Quirke P; Mortensen N; Maraveyas A; Meadows HM; Ledermann J; Sebag-Montefiore D
Ann Oncol; 2014 Jul; 25(7):1356-1362. PubMed ID: 24718885
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of capecitabine and oxaliplatin given prior to and concurrently with preoperative pelvic radiotherapy in patients with locally advanced rectal cancer.
Koeberle D; Burkhard R; von Moos R; Winterhalder R; Hess V; Heitzmann F; Ruhstaller T; Terraciano L; Neuweiler J; Bieri G; Rust C; Toepfer M
Br J Cancer; 2008 Apr; 98(7):1204-9. PubMed ID: 18349837
[TBL] [Abstract][Full Text] [Related]
19. Pilot study of intense neoadjuvant chemoradiotherapy for locally advanced rectal cancer: retrospective review of a phase II study.
Xu BH; Chi P; Guo JH; Guan GX; Tang TL; Yang YH; Chen MQ; Song JY; Feng CY
Tumori; 2014; 100(2):149-57. PubMed ID: 24852858
[TBL] [Abstract][Full Text] [Related]
20. Four-week neoadjuvant intensity-modulated radiation therapy with concurrent capecitabine and oxaliplatin in locally advanced rectal cancer patients: a validation phase II trial.
Arbea L; Martínez-Monge R; Díaz-González JA; Moreno M; Rodríguez J; Hernández JL; Sola JJ; Ramos LI; Subtil JC; Nuñez J; Chopitea A; Cambeiro M; Gaztañaga M; García-Foncillas J; Aristu J
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):587-93. PubMed ID: 22079731
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
